Cargando…

Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis

In multiple sclerosis (MS), treatment with the monoclonal antibody natalizumab effectively reduces the formation of acute lesions in the central nervous system (CNS). Natalizumab binds the integrin very late antigen (VLA)-4, expressed on the surface of immune cells, and inhibits VLA-4 dependent tran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Börnsen, Lars, Christensen, Jeppe Romme, Ratzer, Rikke, Oturai, Annette Bang, Sørensen, Per Soelberg, Søndergaard, Helle Bach, Sellebjerg, Finn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511477/ https://www.ncbi.nlm.nih.gov/pubmed/23226199 http://dx.doi.org/10.1371/journal.pone.0047578

Ejemplares similares

Pregnancy-Induced Changes in microRNA Expression in Multiple Sclerosis
por: Søndergaard, Helle Bach, et al.
Publicado: (2021)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
por: Romme Christensen, Jeppe, et al.
Publicado: (2012)

Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression
por: Christensen, Jeppe Romme, et al.
Publicado: (2013)

Correction: Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression
por: Romme Christensen, Jeppe, et al.
Publicado: (2013)

Progressive multiple sclerosis, cognitive function, and quality of life
por: Højsgaard Chow, Helene, et al.
Publicado: (2018)

Endogenous Interferon-β-Inducible Gene Expression and Interferon-β-Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2015)

Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls
por: Buhelt, Sophie, et al.
Publicado: (2019)

Endogenous and Recombinant Type I Interferons and Disease Activity in Multiple Sclerosis
por: Sellebjerg, Finn, et al.
Publicado: (2012)

Pulsed immune reconstitution therapy in multiple sclerosis
por: Sorensen, Per Soelberg, et al.
Publicado: (2019)

IL2RA Methylation and Gene Expression in Relation to the Multiple Sclerosis-Associated Gene Variant rs2104286 and Soluble IL-2Rα in CD8(+) T Cells
por: Buhelt, Sophie, et al.
Publicado: (2021)

Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis
por: Carrión, Belinda, et al.
Publicado: (2021)

Absence of systemic oxidative stress and increased CSF prostaglandin F(2α) in progressive MS
por: Lam, Magda A., et al.
Publicado: (2016)

Serum Short-Chain Fatty Acids and Associations With Inflammation in Newly Diagnosed Patients With Multiple Sclerosis and Healthy Controls
por: Olsson, Anna, et al.
Publicado: (2021)

Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial
por: Højsgaard Chow, Helene, et al.
Publicado: (2021)

Imaging cortical multiple sclerosis lesions with ultra-high field MRI
por: Madsen, Mads A.J., et al.
Publicado: (2021)

The gut microbiota in multiple sclerosis varies with disease activity
por: Thirion, Florence, et al.
Publicado: (2023)

Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-α and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis
por: Nielsen, Claus H., et al.
Publicado: (2016)

The association of selected multiple sclerosis symptoms with disability and quality of life: a large Danish self-report survey
por: Gustavsen, S., et al.
Publicado: (2021)

Pregnancy outcomes after early fetal exposure to injectable first‐line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis
por: Andersen, Johanna Balslev, et al.
Publicado: (2022)

Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis
por: Dogonowski, Anne-Marie, et al.
Publicado: (2016)

The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis
por: Hasselbalch, IC, et al.
Publicado: (2018)

Linking lesions in sensorimotor cortex to contralateral hand function in multiple sclerosis: a 7 T MRI study
por: Madsen, Mads A J, et al.
Publicado: (2022)

IL-6, IL-12, and IL-23 STAT-Pathway Genetic Risk and Responsiveness of Lymphocytes in Patients with Multiple Sclerosis
por: von Essen, Marina R., et al.
Publicado: (2019)

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination
por: Al Nimer, Faiez, et al.
Publicado: (2016)

The interaction between smoking and HLA genes in multiple sclerosis: replication and refinement
por: Hedström, Anna Karin, et al.
Publicado: (2017)

The Effect of Cannabis-Based Medicine on Neuropathic Pain and Spasticity in Patients with Multiple Sclerosis and Spinal Cord Injury: Study Protocol of a National Multicenter Double-Blinded, Placebo-Controlled Trial
por: Hansen, Julie Schjødtz, et al.
Publicado: (2021)

The transcriptome of peripheral blood mononuclear cells in patients with clinical subtypes of late age-related macular degeneration
por: Subhi, Yousif, et al.
Publicado: (2019)

Comorbidity in Multiple Sclerosis
por: Magyari, Melinda, et al.
Publicado: (2020)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Inflammatory vaginitis associated with long-term rituximab treatment in a patient with multiple sclerosis
por: Filikci, Zuhal, et al.
Publicado: (2022)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Oligoclonal Band Status in Scandinavian Multiple Sclerosis Patients Is Associated with Specific Genetic Risk Alleles
por: Mero, Inger-Lise, et al.
Publicado: (2013)

The Danish Multiple Sclerosis Treatment Register
por: Magyari, Melinda, et al.
Publicado: (2016)

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis
por: Bachelet, Delphine, et al.
Publicado: (2016)

Intrathecal CD8(+)CD20(+) T Cells in Primary Progressive Multiple Sclerosis
por: von Essen, Marina Rode, et al.
Publicado: (2023)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Glioblastoma in natalizumab‐treated multiple sclerosis patients
por: Sierra Morales, Fabian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6ksp30lrdan93ja1knecqpains